CRDF250117P4000
- 0.35
- 0.000.00%
Cardiff Oncology Newsroom
While Institutions Own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), Retail Investors Are Its Largest Shareholders With 57% Ownership
James Levine Bought 13% More Shares In Cardiff Oncology
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Piper Sandler Maintains Overweight on Cardiff Oncology, Raises Price Target to $10
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Director Gary Pace Buys $940,199 in Stock
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'
What's Going On With Cardiff Oncology Stock On Tuesday?
Cardiff Oncology Shares Rise 45% On Initial Positive Results in Colon Cancer Trial
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Cardiff Oncology (CRDF) Gets a Buy From Craig-Hallum
Sector Update: Health Care
Top Premarket Gainers
Express News | Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Cardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell